Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa.

Expert opinion on emerging drugs - 1 Dec 2022

Martinez-Fernandez de la Camara Cristina, Cehajic-Kapetanovic Jasmina, MacLaren Robert E

Abstract excerpt

INTRODUCTION: Mutations in the RPGR gene are responsible for one of the most prevalent and severe types of retinitis pigmentosa. Gene therapy has shown great promise to treat inherited retinal diseases, and currently, four RPGR gene therapy vectors are being evaluated in clinical trials. AREAS COVERED: This manuscript reviews the gene therapy products that are in development for X-linked retinitis pigmentosa...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Codon
Share to Eye Proteins
Share to Genetic Therapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Retinal Development and Disorders

Share to Retinal Diseases and Treatments

Share to Retinitis Pigmentosa

Share to Retinopathy of Prematurity Studies

Source

Identifiers

PMID: 36562395
DOI: 10.1080/14728214.2022.2152003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa.PMID 36562395Read ↗

X-Linked Retinitis Pigmentosa Gene Therapy: Preclinical AspectsSemantic proximity Read ↗

Pre-Clinical and Clinical Advances in Gene Therapy of X-Linked Retinitis Pigmentosa: Hope on the HorizonSemantic proximity Read ↗

Molecular Strategies for RPGR Gene TherapySemantic proximity Read ↗

Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR.Semantic proximity Read ↗

RPGR-Related Retinopathy: Clinical Features, Molecular Genetics, and Gene Replacement Therapy.Semantic proximity Read ↗

Gene Therapy for Retinitis Pigmentosa: Current Challenges and New Progress.Semantic proximity Read ↗

RPGR and RP2: targets for the treatment of X-linked retinitis pigmentosa?Semantic proximity Read ↗

Retinitis Pigmentosa: Progress in Molecular Pathology and Biotherapeutical StrategiesSemantic proximity Read ↗

Codon-Optimized RPGR Improves Stability and Efficacy of AAV8 Gene Therapy in Two Mouse Models of X-Linked Retinitis Pigmentosa.Semantic proximity Read ↗

The New Era of Therapeutic Strategies for the Treatment of Retinitis Pigmentosa: From Pathomolecular Mechanisms to the Development of Cell-Based TherapiesSemantic proximity Read ↗

Genetic treatment for autosomal dominant inherited retinal dystrophies: approaches, challenges and targeted genotypes.Semantic proximity Read ↗

Gene therapy for inherited retinal diseases: progress and possibilitiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.